Advertisement

Topics

Basilea gets rights to ArQule's derazantinib

15:40 EDT 17 Apr 2018 | Elsevier Business Intelligence

Basilea Pharmaceutica Ltd. licensed exclusive global rights (excluding China, Hong Kong, Macau, and Taiwan) to develop, manuf...

Original Article: Basilea gets rights to ArQule's derazantinib

NEXT ARTICLE

More From BioPortfolio on "Basilea gets rights to ArQule's derazantinib"

Advertisement
Quick Search
Advertisement
Advertisement